JPRN-C000000290
Completed
Phase 2
Phase II study of imatinib mesylate for treatment of Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in children: A Japanese Cooperative Trial - Ph+ ALL04
Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)0 sites56 target enrollmentDecember 1, 2005
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Philadelphia Chromosome-positive acute lymphoblastic leukemia
- Sponsor
- Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
- Enrollment
- 56
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Intracranial hemorrhage. Heart failure requiring treatment. Chronic renal failure. Active uncontrolled infections. Diabetes mellitus. Liver chirrhosis. Patient with any significant history of non\-compliance to medical regimens or with inability to grant reliable informed consent. Female patients who are pregnant or breast\-feeding.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryAcral Lentiginous Malignant MelanomaRecurrent MelanomaStage IIIA MelanomaStage IIIB MelanomaStage IIIC MelanomaStage IV MelanomaNCT00470470National Cancer Institute (NCI)30
Active, not recruiting
Phase 1
Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic LeukemiaPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL)Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2017-001805-34-Outside-EU/EEAovartis Pharma K.K20
Completed
Phase 2
Imatinib Mesylate in Treating Patients With Stage IV Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00041340National Cancer Institute (NCI)37
Active, not recruiting
Phase 1
A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 20.0 Level: LLT Classification code 10062427 Term: Gastrointestinal stromal tumor System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1 Level: PT Classification code 10051066 Term: Gastrointestinal stromal tumour System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-GBEuropean Organisation for Research and Treatment of Cancer76
Active, not recruiting
Not Applicable
A randomised phase II trial of imatinib alternating withregorafenib compared to imatinib alone for the first linetreatment of advanced gastrointestinal stromal tumour (GIST)unresectable metastatic GISTMedDRA version: 18.0Level: LLTClassification code 10062427Term: Gastrointestinal stromal tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2015-001298-42-ESEuropean Organisation for Research and Treatment of Cancer240